Benevolent AI (Benevolent AI) Pre-Tax Income : $-91.82 Mil (TTM As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Benevolent AI Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Benevolent AI's pretax income for the three months ended in Dec. 2023 was $-36.62 Mil. Its pretax income for the trailing twelve months (TTM) ended in Dec. 2023 was $-91.82 Mil. Benevolent AI's pretax margin was -1,421.94%.

During the past 6 years, Benevolent AI's highest Pretax Margin was -483.77%. The lowest was -2631.66%. And the median was -1138.52%.

Benevolent AI Pre-Tax Income Historical Data

The historical data trend for Benevolent AI's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Benevolent AI Pre-Tax Income Chart

Benevolent AI Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Pre-Tax Income

Get a 7-Day Free Trial

-78.22

-88.23

-161.85

-219.07

-91.96

Benevolent AI Quarterly Data
	Dec18	Dec19	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Pre-Tax Income	Get a 7-Day Free Trial				-99.70	-183.36	-37.71	-55.21	-36.62

Competitive Comparison of Benevolent AI's Pre-Tax Income

For the Biotechnology subindustry, Benevolent AI's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Benevolent AI's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Benevolent AI's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Benevolent AI's Pre-Tax Income falls into.

Benevolent AI Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Benevolent AI's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-96.858	+	0	+	-0.413	+	4.886	+	0.423
	=	-91.96

Benevolent AI's Pretax Income for the quarter that ended in Dec. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-45.516	+	0	+	-0.19	+	2.382	+	6.709
	=	-36.62

Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-91.82 Mil.

Benevolent AI (GREY:BAIVF) Pre-Tax Income Explanation

Benevolent AI's Pretax Margin for the quarter that ended in Dec. 2023 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	-36.615	/	2.575
	=	-1,421.94%

During the past 6 years, Benevolent AI's highest Pretax Margin was -483.77%. The lowest was -2631.66%. And the median was -1138.52%.

Benevolent AI Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Benevolent AI's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Benevolent AI (Benevolent AI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Benevolent AI (GREY:BAIVF) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

BAI:Netherlands 2XA:Germany

Address

4-8 Maple Street, London, GBR, W1T 5HD

Website

https://www.benevolent.com

Benevolent AI is a clinical-stage AI-enabled drug discovery company. It delivers novel drug candidates with a higher probability of clinical success than those developed using traditional methods. The Benevolent Platform powers a growing in-house pipeline of over 20 drug programmes, spanning from target discovery to clinical studies, and it maintains commercial collaborations with pharmaceutical companies.